Noxopharm Ltd has released a press release.
New funds from Nyrada share sales
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Noxopharm
- March 2025 Quarterly Activities Report and Appendix 4C
- Appendix 4D and FY2025 Half Year Financial Report
- SOF-SKN passes required in vitro safety tests
- December 2024 Quarterly Activities Report and Appendix 4C
- Additional convertible note for long-term shareholder
Later from Noxopharm
- Green light for HERACLES clinical trial
- Promising Sofra results from overseas company
- First SOF-SKN dose in HERACLES clinical trial
- HERACLES clinical trial - Update 1
- June 2025 Quarterly Activities Report and Appendix 4C
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm